Sonata Therapeutics
Francesco Marincola currently serves as the Chief Scientific Officer at Sonata Therapeutics since March 2023 and holds the position of Global Head of Research at Kite Pharma since January 2021. Additionally, Marincola is the President and Chief Scientific Officer at Refuge Biotechnologies and has been associated with AbbVie as a Distinguished Research Fellow since February 2017. As Chief Research Officer at Sidra Medical and Research Center since March 2013, responsibilities include developing a substantial research institute linked to a women and children's hospital. Previously, Marincola held the title of Tenured Investigator at the National Institutes of Health (NIH) until February 2013. Educational qualifications include a Medical Doctor degree in Immunology and Genetics from the University of Milan, earned between 1972 and 1978.
Sonata Therapeutics
Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences companies. Since 2000, Flagship has originated and fostered the development of nearly 100 scientific ventures resulting in $20+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.